Full-Time

Research Scientist

Computational Structural Biology

Updated on 5/15/2025

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

Compensation Overview

CA$75.2k - CA$94k/yr

+ Equity + Annual Bonus

Senior

Vancouver, BC, Canada

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Python
Requirements
  • PhD in Biochemistry, Biophysics, Structural Biology, Computational Biology, Computer Science, or a related field, or a MSc with 5+ years of related experience in a biological research setting
  • Excellent programming skills in Python
  • Comprehensive understanding of techniques to perform in-silico protein structure design using tools such as Rosetta software suite
  • Working knowledge of antibody structure and function
  • Familiarity with techniques applicable to the molecular design, engineering, and experimental evaluation of antibody and/or antigen libraries for protein engineering purposes
  • Awareness of experimental analytic and biophysics techniques used for antibody characterization, e.g. size exclusion chromatography (SEC), hydrophobic interaction chromatography (HIC), capillary electrophoresis (CE), light scattering (DLS, MALS), differential scanning calorimetry (DSC), isoelectric focusing (IEF), surface plasmon resonance (SPR), etc.
Responsibilities
  • Designing, implementing, and evaluating in-silico protein engineering activities in support of a developing platform for antibody reformatting processes and optimization of therapeutic assets
  • Collaborating with teams across the company to understand engineering challenges and propose solutions
  • Preparing and authoring materials to educate colleagues, and communicate strategies, key findings, and implications
  • Organizing, supporting, and collaborating with other team members to meet project deliverables and timelines
Desired Qualifications
  • Collaborative team player that can contribute to the design, execution, and evaluation of in-silico protein engineering workflows
  • Excited about the opportunity to integrate high throughput protein engineering methods with in-silico tools to solve real-world drug discovery problems
  • Enthusiastic about applying expertise in protein engineering to improve the speed and quality of protein biotherapeutics development
  • Strongly self-motivated and able to work independently to identify project needs and implement solutions

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera focuses on challenging targets that traditional methods struggle to address. The company aims to accelerate the development of new medicines through collaborations, generating revenue from discovery services, licensing agreements, and its own therapeutic programs.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Vancouver, Canada

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • AbCellera's collaboration with AbbVie expands its oncology T-cell engager programs.
  • The partnership with Viking and ArrowMark aims to launch new biotech companies.
  • AbCellera's AI-driven discovery platform enhances precision and speed in drug development.

What critics are saying

  • Increased competition from genomic data leaders like Illumina may impact market share.
  • Strategic misalignments with PE partners could affect AbCellera's operational focus.
  • Rapid AI integration in biotech requires AbCellera to enhance its AI capabilities.

What makes AbCellera Biologics unique

  • AbCellera excels in rapid antibody discovery using a proprietary technology platform.
  • The company has strong partnerships with leading pharmaceutical firms like Eli Lilly.
  • AbCellera's focus on challenging targets sets it apart in the biopharmaceutical market.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Business Wire
May 9th, 2025
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera presents positive preclinical data on ABCL575 at the 2025 SID Annual Meeting.

Montreal Gazette
Mar 25th, 2025
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera announces presentation of in vivo data on PSMA x CD3 T-Cell engagers at AACR 2025.

Stock Titan
Jan 13th, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022.

North Carolina Biotechnology Center
Sep 30th, 2024
Dualogics Sells Antibody Platform to Canadian Company | North Carolina Biotechnology Center

Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.

Stock Titan
Jul 31st, 2024
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs.